Published in Mov Disord on February 15, 2009
Movement disorders reveal Creutzfeldt-Jakob disease. Nat Rev Neurol (2009) 0.75
Stereotypic Movements in Case of Sporadic Creutzfeldt-Jakob Disease: Possible Role of Anti-NMDA Receptor Antibodies. Case Rep Neurol (2012) 0.75
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet (2011) 4.52
Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci (2007) 2.96
Genetic prion disease: the EUROCJD experience. Hum Genet (2005) 2.64
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology (2013) 2.47
MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord (2011) 2.27
GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A (2008) 2.17
Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology (2011) 2.17
MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol (2012) 2.02
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol (2013) 1.83
Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann Neurol (2004) 1.74
Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology (2013) 1.53
Interleukin 4 and interleukin 10 levels are elevated in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Arch Neurol (2005) 1.53
Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem (2012) 1.52
Polysomnographic findings, video-based sleep analysis and sleep perception in progressive supranuclear palsy. Sleep Med (2008) 1.48
Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med (2012) 1.48
Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World J Biol Psychiatry (2010) 1.45
Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD. Brain (2006) 1.35
Upregulation of cellular prion protein (PrPc) after focal cerebral ischemia and influence of lesion severity. Neurosci Lett (2004) 1.33
Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification. Acta Neuropathol (2009) 1.32
Early detection of abnormal prion protein in genetic human prion diseases now possible using real-time QUIC assay. PLoS One (2013) 1.30
Deletion of cellular prion protein results in reduced Akt activation, enhanced postischemic caspase-3 activation, and exacerbation of ischemic brain injury. Stroke (2006) 1.29
CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain (2006) 1.25
Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain (2012) 1.24
Is there a risk of prion-like disease transmission by Alzheimer- or Parkinson-associated protein particles? Acta Neuropathol (2014) 1.24
Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. J Neurol (2009) 1.21
Characteristic CSF prion seeding efficiency in humans with prion diseases. Mol Neurobiol (2014) 1.19
Rapidly progressive Alzheimer disease. Arch Neurol (2011) 1.19
MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. Brain (2005) 1.18
Clinical features and diagnosis of the MM2 cortical subtype of sporadic Creutzfeldt-Jakob disease. Arch Neurol (2006) 1.15
Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J Alzheimers Dis (2008) 1.14
Immunolocalisation of PrPSc in scrapie-infected N2a mouse neuroblastoma cells by light and electron microscopy. Eur J Cell Biol (2008) 1.14
Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis. J Neurol (2007) 1.12
Genome-wide association study in multiple human prion diseases suggests genetic risk factors additional to PRNP. Hum Mol Genet (2011) 1.12
Intraindividual variability of REM sleep behavior disorder in Parkinson's disease: a comparative assessment using a new REM sleep behavior disorder severity scale (RBDSS) for clinical routine. J Clin Sleep Med (2011) 1.12
Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm (Vienna) (2009) 1.10
Creutzfeldt-Jakob disease in a patient with an R208H mutation of the prion protein gene (PRNP) and a 17-kDa prion protein fragment. Acta Neuropathol (2005) 1.09
Upregulation of miRNA hsa-miR-342-3p in experimental and idiopathic prion disease. Mol Neurodegener (2009) 1.07
Brain-derived proteins in the CSF: do they correlate with brain pathology in CJD? BMC Neurol (2006) 1.06
Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res (2010) 1.06
Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: evaluation of mechanisms. Circulation (2007) 1.06
Camptocormia in idiopathic Parkinson's disease: a focal myopathy of the paravertebral muscles. Mov Disord (2010) 1.04
Computer-aided detection in full-field digital mammography: detection in dependence of the BI-RADS categories. Breast J (2006) 1.04
Decontamination of medical devices from pathological amyloid-β-, tau- and α-synuclein aggregates. Acta Neuropathol Commun (2014) 1.03
Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics (2008) 1.03
Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord (2005) 1.03
Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol (2003) 1.02
Molecular evidence of founder effects of fatal familial insomnia through SNP haplotypes around the D178N mutation. Neurogenetics (2008) 1.02
Radiological assessment of Creutzfeldt-Jakob disease. Eur Radiol (2006) 1.02
Fatal familial insomnia: Clinical features and early identification. Ann Neurol (2008) 1.01
Clinical features of rapidly progressive Alzheimer's disease. Dement Geriatr Cogn Disord (2010) 1.00
Intensity of human prion disease surveillance predicts observed disease incidence. J Neurol Neurosurg Psychiatry (2013) 1.00
Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett (2004) 0.99
Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. J Alzheimers Dis (2009) 0.98
Blood-based neurochemical diagnosis of vascular dementia: a pilot study. J Neurochem (2007) 0.96
Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements. Int J Mol Med (2006) 0.96
Antimicrobial effectiveness of a highly concentrated chlorhexidine varnish treatment in teenagers with fixed orthodontic appliances. Angle Orthod (2006) 0.96
Prion protein helix1 promotes aggregation but is not converted into beta-sheet. J Biol Chem (2006) 0.96
Urinary alpha1-antichymotrypsin: a biomarker of prion infection. PLoS One (2008) 0.96
Impact of vCJD on blood supply. Biologicals (2007) 0.95
Genome-wide study links MTMR7 gene to variant Creutzfeldt-Jakob risk. Neurobiol Aging (2011) 0.95
Brain biopsy in patients with suspected Creutzfeldt-Jakob disease. J Neurosurg (2008) 0.95
The role of SCARB2 as susceptibility factor in Parkinson's disease. Mov Disord (2013) 0.94
Affective and cognitive Theory of Mind in patients with parkinson's disease. Parkinsonism Relat Disord (2010) 0.94
High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease. Brain (2014) 0.94
Cerebrospinal fluid biomarkers in Alzheimer's disease, vascular dementia and ischemic stroke patients: a critical analysis. J Neurol (2013) 0.93
T2*-weighted MRI in diagnosis of multiple system atrophy. A practical approach for clinicians. J Neurol (2007) 0.93
Similarities between forms of sheep scrapie and Creutzfeldt-Jakob disease are encoded by distinct prion types. Am J Pathol (2009) 0.93
Pro- and anti-inflammatory cytokines in the CSF of patients with Creutzfeldt-Jakob disease. J Neuroimmunol (2005) 0.92
Impact of breast density on computer-aided detection in full-field digital mammography. J Digit Imaging (2006) 0.92
TGF-beta 1 enhances neurite outgrowth via regulation of proteasome function and EFABP. Neurobiol Dis (2010) 0.92
Positron emission tomography with [(18)F]FDG in the diagnosis of Creutzfeldt-Jakob disease (CJD). J Neurol (2002) 0.92
Age, drugs, or disease: what alters the macrostructure of sleep in Parkinson's disease? Sleep Med (2012) 0.92
Detection of infectivity in blood of persons with variant and sporadic Creutzfeldt-Jakob disease. Emerg Infect Dis (2014) 0.91
Rapidly progressive Alzheimer's disease: a multicenter update. J Alzheimers Dis (2012) 0.91
Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening. J Biol Chem (2012) 0.90
Latrogenic Creutzfeldt-Jakob disease with florid plaques. Brain Pathol (2003) 0.90
Extracellular vesicle sorting of α-Synuclein is regulated by sumoylation. Acta Neuropathol (2015) 0.90
Variants in eukaryotic translation initiation factor 4G1 in sporadic Parkinson's disease. Neurogenetics (2012) 0.90
Therapeutic approaches for prion disorders. Expert Rev Anti Infect Ther (2007) 0.90
Clinical course in young patients with sporadic Creutzfeldt-Jakob disease. Ann Neurol (2005) 0.89